8-K: 180 Life Sciences Corp. Appoints Jay Goodman to Board of Directors, Expanding Expertise in SaaS and iGaming

180 Life Sciences Corp. has appointed Jay Goodman, a seasoned executive with experience in SaaS and iGaming, to its Board of Directors, effective October 24, 2024.

Summary

• 180 Life Sciences Corp. appointed Jay Goodman to its Board of Directors, effective October 24, 2024.
• Mr. Goodman will serve as a Class I director until the 2025 Annual Meeting of Stockholders.
• The Board has set its size at five members.
• Mr. Goodman has been deemed independent according to Nasdaq rules.
• He is the son of Anthony Brian Goodman, CEO of Elray Resources, which holds convertible preferred stock in 180 Life Sciences.
• Mr. Goodman will receive an annual retainer of $50,000 and an additional $15,000 for chairing the Compensation Committee.
• He has the option to receive half of his compensation in stock.
• Blair Jordan's offer letter was terminated as he is no longer an independent director and is now Interim CEO.
• Mr. Goodman has over 10 years of experience in the SaaS industry and 6+ years in the iGaming industry.
• He has held leadership roles at Docker, Confluent, and Skywind Games, and has been involved in three successful IPOs.

Sentiment

Score: 6

Explanation: The appointment of a new director with relevant experience is a positive development, but the company's non-compliance with Nasdaq listing standards and need for additional funding temper the overall sentiment.

Positives

• The appointment of Jay Goodman brings significant experience in SaaS and iGaming to the Board.
• Mr. Goodman's experience includes leadership roles and involvement in successful IPOs.
• His independence as a director aligns with Nasdaq requirements.
• The compensation structure provides flexibility with the option to receive stock.

Negatives

• Blair Jordan's offer letter was terminated, indicating a change in his role from independent director to Interim CEO.
• The company is currently not in compliance with Nasdaq's continued listing standards due to its current failure to maintain a three person audit committee and/or a majority of independent directors.

Risks

• The company is not currently in compliance with Nasdaq's continued listing standards.
• The company's ability to raise funding to support its operations and commercialize its newly acquired Gaming Technology Platform is uncertain.
• There is a lack of experience of current management with operating a gaming company.
• The company's ability to generate revenue from the Gaming Technology Platform is uncertain.
• The company needs significant additional funding, which may be dilutive and include onerous terms.
• The company faces competition in the iGaming industry.
• There are risks relating to fraud, theft or cheating.
• The company's ability to obtain and maintain licenses is uncertain.
• The company relies on third party cloud service providers and providers of third-party communications infrastructure, hardware and software.
• The company faces risks regarding the outcome of pharmaceutical studies, the timing and costs thereof, and the ability to obtain sufficient participants.
• The company faces risks regarding the timing of marketing authorization application (MAA) submissions to the UK Medicines and Healthcare products Regulatory Agency (MHRA) and New Drug Application submissions (NDA) to the U.S. Food and Drug Administration (FDA).
• The company faces risks regarding the outcome of clinical trials and the ability to demonstrate safety and efficacy of product candidates.
• The company relies on third parties to conduct its clinical trials, enroll patients, and manufacture its preclinical and clinical drug supplies.
• The company has current negative operating cash flows and a need for additional funding to finance operating plans.
• The company faces potential future litigation involving the Company or the validity or enforceability of the intellectual property of the Company or lawsuits alleging that we have violated the intellectual property of others.
• The company is subject to global economic conditions, geopolitical events and regulatory changes.
• The company is subject to the effect of changing interest rates and inflation, economic downturns and recessions, declines in economic activity or global conflicts.

Future Outlook

The company aims to leverage Mr. Goodman's expertise to expand into the online gaming market and position itself for growth and innovation.

Management Comments

• We are thrilled to welcome Mr. Goodman to our Board, said Blair Jordan, Interim CEO of 180.
• His depth of experience in SaaS, coupled with his extensive background in iGaming and leadership, will be instrumental to our company's evolving strategy.
• As we expand into the online gaming market, his proven track record in guiding companies through rapid growth and market transitions will be invaluable.

Industry Context

The appointment of a director with SaaS and iGaming experience reflects 180 Life Sciences' strategic move into the online gaming sector, aligning with the growing trend of biotechnology companies diversifying into related technology markets.

Comparison to Industry Standards

• The appointment of an independent director with relevant industry experience is a common practice for companies listed on the Nasdaq.
• The compensation structure, including a retainer fee and additional compensation for committee leadership, is typical for board members of publicly traded companies.
• The company's move into the online gaming sector is a strategic shift, and the appointment of Mr. Goodman is intended to provide the necessary expertise for this transition.
• The company's current non-compliance with Nasdaq listing standards regarding the audit committee and independent directors is a concern and needs to be addressed to meet industry best practices.

Management Changes

Corporate Governance

Related Party Transactions

• Mr. Goodman is the son of Anthony Brian Goodman, CEO of Elray Resources, which holds convertible preferred stock in 180 Life Sciences.

Stakeholder Impact

• Shareholders may view the appointment of an experienced director positively.
• Employees may be impacted by the company's strategic shift into the online gaming sector.
• Customers may be impacted by the company's new focus on the online gaming market.
• Creditors may be impacted by the company's need for additional funding.

Next Steps

• Mr. Goodman will serve on the Nominating and Corporate Governance Committee and the Audit Committee.
• Mr. Goodman will chair the Compensation Committee.
• The company will enter into a standard Indemnity Agreement with Mr. Goodman.
• The company will seek stockholder approval for Mr. Goodman's appointment at the next annual meeting.

Key Dates

Keywords

Board of Directors, Jay Goodman, SaaS, iGaming, Independent Director, Compensation Committee, Nasdaq, 180 Life Sciences Corp, Corporate Governance, Executive Appointment